MX2020011196A - Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. - Google Patents

Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.

Info

Publication number
MX2020011196A
MX2020011196A MX2020011196A MX2020011196A MX2020011196A MX 2020011196 A MX2020011196 A MX 2020011196A MX 2020011196 A MX2020011196 A MX 2020011196A MX 2020011196 A MX2020011196 A MX 2020011196A MX 2020011196 A MX2020011196 A MX 2020011196A
Authority
MX
Mexico
Prior art keywords
indacen
hexahydro
sulfonamide
pyrazole
isopropyl
Prior art date
Application number
MX2020011196A
Other languages
English (en)
Inventor
David Miller
Angus Macleod
Rio Gancedo Susana Del
Samuel Alexander Stratford
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of MX2020011196A publication Critical patent/MX2020011196A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una sal sódica de N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1 H-pirazol-3-sulfonamida y a hidratos, solvatos y formas polimórficas de estos. La presente invención se refiere además a composiciones farmacéuticas que comprenden este compuesto y al uso de este compuesto en el tratamiento y la prevención de trastornos y enfermedades médicos, más especialmente por inhibición de NLRP3.
MX2020011196A 2018-04-23 2019-04-23 Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. MX2020011196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1806578.9A GB201806578D0 (en) 2018-04-23 2018-04-23 Novel compound
PCT/EP2019/060311 WO2019206871A1 (en) 2018-04-23 2019-04-23 A sodium salt of n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide

Publications (1)

Publication Number Publication Date
MX2020011196A true MX2020011196A (es) 2020-11-13

Family

ID=62236309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011196A MX2020011196A (es) 2018-04-23 2019-04-23 Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.

Country Status (27)

Country Link
US (2) US10973803B2 (es)
EP (2) EP3722281A1 (es)
JP (1) JP7382958B2 (es)
KR (1) KR20210005589A (es)
CN (1) CN112020495B (es)
AR (1) AR114827A1 (es)
AU (1) AU2019257973A1 (es)
BR (1) BR112020021650A2 (es)
CA (1) CA3097832A1 (es)
CY (1) CY1123260T1 (es)
DK (1) DK3606909T3 (es)
ES (1) ES2811228T3 (es)
GB (1) GB201806578D0 (es)
HR (1) HRP20201263T1 (es)
HU (1) HUE050369T2 (es)
LT (1) LT3606909T (es)
MA (2) MA48051B1 (es)
MD (1) MD3606909T2 (es)
ME (1) ME03822B (es)
MX (1) MX2020011196A (es)
PL (1) PL3606909T3 (es)
PT (1) PT3606909T (es)
RS (1) RS60646B1 (es)
SI (1) SI3606909T1 (es)
TW (1) TW201943704A (es)
UY (1) UY38186A (es)
WO (1) WO2019206871A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190356A (es) 2017-01-23 2019-11-20 Genentech Inc Compuestos químicos como inhibidores de la actividad de la interleuquina-1
WO2018215818A1 (en) 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
CN111093773A (zh) 2017-08-15 2020-05-01 英夫拉索姆有限公司 作为nlrp3抑制剂的磺酰脲和磺酰硫脲
RU2020115098A (ru) 2017-11-09 2021-12-10 Инфлазоум Лимитед Соединения новых сульфонамидкарбоксамидов
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759078A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
CN112437683A (zh) 2018-07-20 2021-03-02 豪夫迈·罗氏有限公司 用作白细胞介素-1 活性抑制剂的磺酰脲类化合物
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
WO2021089776A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment and prevention of a traumatic brain disorder
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment
US20220409585A1 (en) * 2019-11-07 2022-12-29 Inflazome Limited Treatment of autoinflammatory disorders
WO2021089769A1 (en) 2019-11-07 2021-05-14 Inflazome Limited Treatment and prevention of neuroinflammation or an inflammatory brain disorder
WO2021089781A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide
CN114641287A (zh) * 2019-11-07 2022-06-17 英夫拉索姆有限公司 神经退行性病症的治疗和预防
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802908A (en) * 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
AU6464400A (en) * 1999-09-14 2001-04-17 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
WO2013031931A1 (ja) * 2011-09-02 2013-03-07 協和発酵キリン株式会社 ケモカイン受容体活性調節剤
EP3888749A1 (en) * 2015-02-16 2021-10-06 The University of Queensland Sulfonylureas and related compounds and use of same
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA44225A (fr) 2016-02-16 2018-12-26 The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv Sulfonylurées et composés apparentés et leur utilisation
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
AU2017254522B2 (en) 2016-04-18 2021-09-23 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes

Also Published As

Publication number Publication date
EP3606909A1 (en) 2020-02-12
UY38186A (es) 2019-11-29
WO2019206871A1 (en) 2019-10-31
KR20210005589A (ko) 2021-01-14
LT3606909T (lt) 2020-10-12
US10973803B2 (en) 2021-04-13
BR112020021650A2 (pt) 2021-01-26
CY1123260T1 (el) 2021-12-31
DK3606909T3 (da) 2020-08-24
MA51082A (fr) 2021-05-19
ME03822B (me) 2021-04-20
PT3606909T (pt) 2020-07-09
CN112020495A (zh) 2020-12-01
HRP20201263T1 (hr) 2021-02-05
US20210315862A1 (en) 2021-10-14
ES2811228T3 (es) 2021-03-11
US20200237723A1 (en) 2020-07-30
GB201806578D0 (en) 2018-06-06
HUE050369T2 (hu) 2020-11-30
EP3722281A1 (en) 2020-10-14
TW201943704A (zh) 2019-11-16
SI3606909T1 (sl) 2020-09-30
MD3606909T2 (ro) 2020-08-31
AR114827A1 (es) 2020-10-21
CN112020495B (zh) 2024-05-17
PL3606909T3 (pl) 2020-11-16
JP2021522195A (ja) 2021-08-30
CA3097832A1 (en) 2019-10-31
AU2019257973A1 (en) 2020-11-19
JP7382958B2 (ja) 2023-11-17
RS60646B1 (sr) 2020-09-30
MA48051B1 (fr) 2020-08-31
EP3606909B1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
MX2020011196A (es) Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.
MX2021004431A (es) Procesos novedosos.
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12020551305A1 (en) Pharmaceutical Compounds
JOP20190229B1 (ar) مركبات تثبط بروتين mcl-1
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
EA202191286A1 (ru) Ингибитор 15-pgdh
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
ZA202006071B (en) Antiproliferation compounds and uses thereof
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
MX2021005944A (es) Inhibidores de rip1.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MX2021014458A (es) Compuestos triciclicos.
MX2021014941A (es) Inhibidores de dopamina-b-hidroxilasa.
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19